EXPERIMENTAL TREATMENTS FOR TERMINAL ILLNESSES
- Section 217.5401 - Definitions for KRS 217.5401 to 217.5408
- Section 217.5402 - Manufacturer of investigational drug, biological product, or device may make it available to a requesting patient eligible under KRS 217.5401 to 217.5408
- Section 217.5403 - Eligibility requirements for treatment with investigational drug, biological product, or device
- Section 217.5404 - Written informed consent required for treatment with investigational drug, biological product, or device
- Section 217.5405 - Limitations on impact KRS 217.5401 to 217.5408 may have on insurance coverage or health facility services - Coverage permitted - Approval of health facility for use
- Section 217.5406 - Death of patient receiving experimental treatment absolves heirs of liability for resulting debt
- Section 217.5407 - Health care provider held harmless for recommendation that a patient have access to experimental treatment
- Section 217.5408 - Prohibition against blocking or attempting to block access by eligible patient to experimental treatment
- Section 217.5409 - Renumbered